Terms: = Lymphoma AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA AND Prognosis
9 results:
1. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract] [Full Text] [Related]
2. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape.
Mangolini M; Maiques-Diaz A; Charalampopoulou S; Gerhard-Hartmann E; Bloehdorn J; Moore A; Giachetti G; Lu J; Roamio Franklin VN; Chilamakuri CSR; Moutsopoulos I; Rosenwald A; Stilgenbauer S; Zenz T; Mohorianu I; D'Santos C; Deaglio S; Hodson DJ; Martin-Subero JI; Ringshausen I
Nat Commun; 2022 Oct; 13(1):6220. PubMed ID: 36266281
[TBL] [Abstract] [Full Text] [Related]
3. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.
Guo B; Huang Y; Duan Y; Liao C; Cen H
Cancer Med; 2022 Mar; 11(5):1281-1291. PubMed ID: 35106936
[TBL] [Abstract] [Full Text] [Related]
4. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract] [Full Text] [Related]
6. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract] [Full Text] [Related]
7. Cyclin D1-positive Mediastinal Large B-Cell lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.
Chen BJ; Ruminy P; Roth CG; Bisig B; Mankel B; Steinhilber J; Bohers E; Jardin F; Fend F; Swerdlow SH; Copie-Bergman C; de Leval L; Quintanilla-Martinez L
Am J Surg Pathol; 2019 Jan; 43(1):110-120. PubMed ID: 30211726
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract] [Full Text] [Related]
9. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract] [Full Text] [Related]
